Patient-Reported Outcomes (PROs) from LIBRETTO-431: First-Line Selpercatinib versus Chemotherapy With Pembrolizumab in RET Fusion-positive NSCLC

• DOI: 10.1016/j.jtocrr.2025.100814
• Publication Date: 2025-02-19T17:16:49Z
• Authors: Caicun Zhou; Silvia Novello; Pilar Garrido; Christophe Dooms; Jorge Alatorre-Al...; Niels Reinmuth; Gill Worthy; Kim Cocks; Justin Williams; Hongmei Han; Minji K. Uh; Nalin Payakachat; Adrienne M. Gilligan; Koichi Goto